Results 11 to 20 of about 1,204 (125)

Effectiveness and safety of efgartigimod in patients with anti-NMDAR or anti-LGI1 encephalitis and its ¹⁸F-DPA714 PET imaging evaluation: A multicenter, single-arm, prospective, observational real-world study. [PDF]

Neuroprotection
Abstract Background Efgartigimod disrupts the recycling of pathogenic IgG autoantibodies and may represent a candidate therapy for autoimmune encephalitis. This real‐world study evaluated the clinical efficacy, safety, and impact of efgartigimod on brain inflammation.
Meng H, Tu S, Zhou Y, Shen R, Chen X, Cheng Z, Wang L, Wu Y, Lu J, Wang S, Xu Y, Lin W, Chen S.   +12 more
europepmc   +2 more sources

Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report

Therapeutic Advances in Neurological Disorders
Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness. Severe patients may develop life-threatening respiratory failure and experience crisis.
Xiao Yu Huang, Zhouao Zhang, Xue Du
exaly   +2 more sources

Long-Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis. [PDF]

J Peripher Nerv Syst
ABSTRACT Background and Aims In ADHERE, subcutaneous efgartigimod PH20 (1000 mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open‐label extension of ADHERE assessing long‐term safety and efficacy. Methods Eligible participants from ADHERE run‐in period
Allen JA, Istas G, Kuwabara S, Mole T, Querol L, Rinaldi S, Stettner M, Van Hoorick B, Lewis RA.   +8 more
europepmc   +2 more sources

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. [PDF]

Eur J Neurol
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Meisel A, Marina AD, Doksani P, Hagenacker T, Kleinschnitz C, Krämer HH, Lünemann JD, Meuth SG, Ruck T, Schara-Schmidt U, Schneider-Gold C, Schoser B, Schroeter M, Schubert C, Sieb JP, Zimprich F, Zschüntzsch J, Hoffmann S.   +17 more
europepmc   +2 more sources

FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus

Frontiers in Immunology, 2022
BackgroundImmunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus are debilitating autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal ...
Maud Maho-Vaillant, Maud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, Marie-Laure Golinski, Gestur Vidarsson, Matthias Goebeler, Johanna Stoevesandt, Zsuzsanna Bata-Csörgő, Bianca Balbino, Peter Verheesen, Pascal Joly, Michael Hertl, Sébastien Calbo   +13 more
doaj   +1 more source

Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys

Journal of Immunotoxicology
Efgartigimod is a human IgG1 antibody Fc fragment that reduces IgG levels through neonatal Fc receptor blockade. This study evaluated whether efgartigimod affects the generation of T-cell-dependent antibodies and cellular immune responses to keyhole ...
Ornella Binazon, Mario Cocco, Daniel Thwaites, Christopher Cooper, Mahan Moshir, Peter Vanhoenacker, Dieter Defever, Ariëlla Van de Sompel, Sophie Steeland, Gwenda Pynaert, Peter Ulrichts, Judith Baumeister   +11 more
doaj   +1 more source

Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy

Frontiers in Neurology
BackgroundImmune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.MethodsAll three patients ...
Qiqi Peng, Xiaoping Yao, Sheng Chen, Xiaofeng Li, Feifei Lin, Zhangyu Zou   +5 more
doaj   +1 more source

Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis

Autoimmunity, 2022
Antagonism of the neonatal Fc receptor (FcRn) by efgartigimod has been studied in several autoimmune diseases mediated by immunoglobulin G (IgG) as a therapeutic approach to remove pathogenic IgGs.
Jeffrey T. Guptill, John W. Sleasman, Sophie Steeland, Magdalena Sips, Deborah Gelinas, Hans de Haard, Antoine Azar, Kevin L. Winthrop   +7 more
doaj   +1 more source

Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study

BMJ Neurology Open
Introduction Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in 12–20% of generalised MG (gMG) patients despite immunotherapies.
Lu Zhang, Kan Wang, Yong Hao, Yangtai Guan, Jing Peng, Li Gao, Song Gao, Qiuju Li, Chong Xie, Yuhui Wang, Yanan Wu, Mengze Zhang, Xiaokun Wang, Chunran Xue, Yiwei Yang   +14 more
doaj   +1 more source

Management of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated ...
Hiroyuki Takenaka, Madoka Iida, Yuki Fukami, Masahisa Katsuno   +3 more
wiley   +1 more source